Abstract: TH-PO060
Probiotics in Septic AKI: A Double-Blind, Randomized Control Trial
Session Information
- AKI: Liver Disease, Nephrotoxicity, Novel Therapeutics
November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 102 AKI: Clinical, Outcomes, and Trials
Authors
- Chavez, Jonathan, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Cabrera Aguilar, Jose Said, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Garcia-Garcia, Guillermo, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Alcantar Vallin, Maria de la Luz, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Rodríguez García, Francisco Gonzalo, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Venegas, Miguel Ángel Pérez, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Oseguera Gonzalez, Alexa Nicole, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Barajas, José David González, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Renoirte, Karina, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Hernandez Morales, Karla, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Hernández, Eduardo Manuel, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Background
During sepsis-induced acute kidney injury (AKI), the intestinal microbiota has profound negative changes, this dysbiosis could aggravates AKI. It is possible that modulating the intestinal dysbiosis with probiotics will favor kidney function recovery (KFR) and clinical outcomes.
Methods
In this double-blind clinical trial, patients with sepsis-induced AKI were randomized to receive probiotics or placebo for 7 days. The primary outcome was the rate of KFR by day 7. Secondary outcomes were mortality, kidney replacement therapy (KRT) requirements, urea reduction, modifications in urine volume, electrolyte abnormalities and treatment related adverse events.
Results
A total of 92 patients from February 2019 to March 2022 were randomized, 48 to probiotics and 44 to placebo. Compared to placebo, probiotics did not improve KFR by day 7(HR 0.93, 0.52-1.68, p = 0.81), mortality hazard ratio at 6 months was 0.57 (95%CI 0.32-1.04, p = 0.06). Urea (mg/dL) decreased significantly in the probiotic group from 154 to 80 mg/dl (p = 0.04) as compared to the placebo group (130 to 109 mg/dl (p=0.09). No significant differences were observed with respect to urinary volume, KRT requirement and electrolytes abnormalities. Adverse events were frequent and similar in both groups. (ClinicalTrial.gov NCT03877081) (registered 03/15/2019)
Conclusion
In septic-induced AKI, administration of probiotics for 7 days was safe; however, they did not improve KFR or reduce mortality.